Kourion Therapeutics AG

The company is developing cell therapies for the treatment of bone defects and for myocardial regeneration

The company (as GmbH) was founded by Peter Wernet as spin-off of the University of Düsseldorf, Germany, in November 2000. In September 2003, Kourion was acquired by ViaCell, a wholly owned subsidiary of PerkinElmer .

Berghausener Strasse 98
40764 Langenfeld
Germany
Phone: +49-2173-39220
Fax: +49-2173-3922150

The company’s R&D pipeline is based on a proprietary multi-lineage potential, somatic stem cell (Unrestricted Somatic Stem Cell; USSC) isolated from placental cord blood.

The following section contains a selection of the company’s most relevant patents. For comprehensive patent information please refer to the espacenet databases.